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Abstract
Background: Nebulised dornase alfa is used off-label in critically ill patients. We aimed to assess the benefits and
harms of nebulised dornase alfa versus placebo, no prophylaxis, or hypertonic saline on patient-important outcome
measures in adult critically ill patients.
Methods: We performed a systematic review with meta-analysis and trial sequential analysis (TSA) using the Cochrane
Collaboration methodology. Eligible trials were randomised clinical trials comparing nebulised dornase alfa with placebo,
no prophylaxis, or hypertonic saline. The predefined outcome measures were all-cause mortality, duration of mechanical
ventilation, length of stay, and adverse events. Two reviewers independently assessed trials for inclusion, data extraction,
and risk of bias. Risk ratios (RRs) with 95 % confidence intervals (CIs) were estimated by conventional cumulative
meta-analysis, and the robustness of the primary estimate was assessed by TSA.
Results: Two trials (n = 63) were included; both were judged to have high risk of bias. There was no statistically
significant difference in mortality (random effects model RR (95 % CI) 0.73 (0.09–5.77); P = 0.24; I2 = 30 %). TSA
could not be conducted because less than 1 % of the required information size had been accrued. None of the
two trials reported adequate and detailed data on any of the secondary outcome measures.
Conclusions: We found very low quantity and quality of evidence for use of nebulised dornase alfa in adult critically ill
patients in this systematic review with meta-analysis.
Systematic review registration: The International Prospective Register of Systematic Reviews (PROSPERO), no.
CRD442015016047.
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Background
Dornase alfa (Pulmozyme) is a nebulised recombinant hu-
man deoxyribonuclease I (rhDNase) approved and used in
patients with cystic fibrosis (CF) [1]. It is a 260-amino acid
glycoprotein with 2.5 mg of active drug for nebulization
once or twice daily. It reduces the viscosity of the mucus
in a dose-dependent fashion in patients with CF, and long-
term use results in improved lung function [2], but the ef-
fect on mortality is inconclusive [2].
There appears to be an increasing use of dornase alfa
outside the clinical context of CF, including in patients
with empyema [3], atelectasis [4], asthma [5], and sinusitis
[6]. A possible benefit of dornase alfa in adult critically ill
patients with atelectasis and mucus plugging has been
suggested, and clinical use in the intensive care unit (ICU)
has been reported [1]. However, in a recent review, it was
concluded that there is insufficient evidence for the* Correspondence: mortenhylander@gmail.com
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efficacy of dornase alfa use in pediatric patients with non-
CF pulmonary atelectasis [7].
The aim of the present systematic review was to assess
the benefits and harms of dornase alfa versus placebo or
hypertonic saline on patient-important outcome mea-
sures in adult critically ill patients. We hypothesized that
there is very little evidence supporting off-label use of
dornase alfa in adult critically ill patients.
Methods
This systematic review is based on the methodology rec-
ommended by the Cochrane Collaboration [8], and the
manuscript has been prepared according to the PRISMA
statement (Additional file 1) [9]. The protocol has been
published in the International Prospective Register of Sys-
tematic Reviews (PROSPERO), no. CRD42015016047.
Eligibility criteria
Potentially eligible trials had to be randomised; include
adult critically ill patients; have an intervention group
that received inhaled dornase alfa in any dose and of
any duration; and a control group that received no
treatment, placebo, or hypertonic saline. We included
trials irrespective of language, blinding, publication sta-
tus, and number of intervention groups. Exclusion cri-
teria were trials in animals, trials in pediatric patients,
trials in patients with CF, and trials not reporting the
patient-important outcome measures [10, 11] outlined
in the protocol, e.g., changes on chest radiograph or in
gas exchange.
Outcome measures
The predefined primary and secondary outcome measures
were as follows: all-cause mortality at the longest follow-
up (primary), duration of mechanical ventilation, length of
stay in ICU, length of stay in hospital, and adverse events
(secondary). The outcome measures were defined as by
the authors of the included trials.
Search strategy
We framed the following clinical research question: “Is
treatment with nebulised dornase alfa in adult critically
ill patients superior to no treatment, placebo or hyper-
tonic saline?”
A population, intervention, comparator, and out-
comes (PICO)-based question and literature search was
created [12]:
Population: critically ill OR icu OR intensive care unit
OR intensive care
Intervention: recombinant human deoxyribonuclease
OR dornase alpha OR recombinant human DNase OR
rhDNase OR Pulmozyme
Comparator: control OR placebo OR hypertonic saline
Outcomes: mortality OR death OR mechanical
ventilation OR intermittent positive pressure
ventilation OR length of stay OR LOS OR adverse
events OR morbidity
The following databases were searched for literature:
MEDLINE including MeSH (January 1966 to January
2015), Embase (January 1980 to January 2015) and the
Cochrane Library (Issue 3, January 2015). The detailed
search strategy is available as an additional file (Additional
file 2). We also hand-searched the reference lists of the in-
cluded trials and other relevant reviews, and data from
unpublished trials were explored. The electronic literature
search was last updated 9 September 2015.
Study selection
Two authors (CC and MHM) independently reviewed all
titles and abstracts identified in the literature search and
excluded trials that were obviously not relevant. The
remaining trials were evaluated in full-text. Disagree-
ments were resolved with AP.
Data extraction
Two authors (CC and MHM) independently extracted in-
formation from each included trial using a data extraction
form. The extracted information included trial character-
istics (year of publication, trial duration, and country);
characteristics of the trial participants (inclusion and ex-
clusion criteria); type of intervention/control (name, dos-
ing, duration, and comparator); outcomes; and risk of
bias. The corresponding authors of the included trials
were sought contacted electronically for additional details;
however, no one responded.
Risk of bias assessment
In order to evaluate the risk of systematic errors in the in-
cluded trials, two authors (CC and MHM) independently
assessed the risk of bias as advised by the Cochrane Col-
laboration [8], including the domains of random sequence
generation, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting, baseline im-
balance, and bias due to vested financial interest. If one or
more domains were judged as being high or unclear, we
classified the trial as having an overall high risk of bias [8].
Disagreements were resolved with AP.
Statistical analyses
For each included trial, we calculated relative risk (RR)
with 95 % confidence intervals (CIs) for dichotomous out-
come measures and mean difference (MD) with 95 % CI
for continuous outcome measures, and we pooled these
measures in conventional cumulative meta-analyses. Stat-
istical heterogeneity among trials was quantified with in-
consistency factor (I2) [13] and diversity (D2) statistics
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[14]. If the I2 statistic was 0, we reported the results from
a fixed effects model, and if the I2 statistic was >0, we re-
ported results from a random effects model (the most
conservative estimate).
We used chi-squared test to provide an indication of
heterogeneity between studies (test-of-interaction); P <
0.10 was considered significant.
The risk of random errors in the cumulative meta-
analyses was assessed by trial sequential analyses (TSA)
[14–16]. TSA is a sample size calculation (interim analysis)
for meta-analyses that widens the confidence intervals in
case data are too sparse to draw firm conclusions (repetitive
testing). We conducted TSA with the intention to maintain
an overall 5 % risk of a type I error and a power of 80 %.
For the calculation of the required information size, we
used a 20 % relative risk reduction (RRR) of the interven-
tion effect for the dichotomous outcome measures, and for
the continuous outcome measures, the required informa-
tion size was based on a calculated value based on the in-
cluded trials [17]. If—according to the TSA—less than 5 %
of the D2-adjusted required information size (DIS) has been
accrued, no TSA details or plots are presented.
A sensitivity analysis with application of continuity
correction in trials of zero events was conducted [18].
Risk of small trial bias by means of funnel plot was
abandoned because less than ten trials were included [8].
Review Manager 5.2 (the Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, Denmark) was used
for the conventional meta-analyses, and for the TSA, we
used the TSA program version 0.9 beta [17].
Subgroup analyses
The following predefined subgroup analyses were planned:
(1)Comparing estimates of the pooled intervention
effect in trials with low risk of bias to estimates from
trials with high risk of bias (hypothesized direction
of subgroup effect: increased intervention effect in
trials with high risk of bias).
(2)Comparing estimates of the pooled intervention
effect in trials conducted in mechanically ventilated
patients versus non-mechanically ventilated patients
(hypothesized direction of subgroup effect: increased
intervention effect in mechanically ventilated patients).
(3)Comparing estimates of the pooled intervention
effect in trials using no treatment/placebo as
comparator versus trials using hypertonic saline as
comparator (hypothesized direction of subgroup
effect: increased intervention effect in trials using
placebo as comparator).
Only the third subgroup analysis could be conducted
and reported, as neither trial had overall low risk of bias
nor included non-mechanically ventilated patients.
Results
A total of two trials were included [19, 20] (Additional file
1 and Table 1). The main reason for exclusion was that
the trials were conducted in patients with CF and/or
pediatric patients. One trial was excluded because the
population was non-critically ill patients with asthma
(treatment in the emergency department with only half of
the patients subsequently hospitalized) [5].
Characteristics of trials
Both trials were single-centre trials from the USA and
included patients from mixed ICUs (Table 1).
Participants
The two included trials enrolled a total of 63 adult critic-
ally ill patients, whom were all mechanically ventilated.
The trial inclusion and exclusion criteria were somewhat
homogenous (Table 1).
Intervention and comparators
Both trials evaluated nebulised dornase alfa 2.5 mg twice
daily versus nebulised placebo twice daily, and one [20]
also assessed nebulised hypertonic saline twice daily as
comparator (three-armed design).
Risk of bias
No trials were judged to be of low risk of bias in all six
domains (Fig. 1). The main reasons for high risk of bias
were unclear/high risk of attrition bias and reporting
bias, as secondary outcome measures were inadequately
reported or supplied upon request, and because of inad-
equate duration of follow-up [19]. Furthermore, one trial
had potential financial bias because the company provid-
ing dornase alfa funded the trial [19].
Outcome measures
All-cause mortality
Mortality data were obtained from both trials including 63
patients in total. The conventional meta-analysis showed
no difference in mortality in patients treated with dornase
alfa compared with the control group: random effects
model RR (95 % CI) 0.73 (0.09–5.77); P = 0.24; I2 = 30 %
(Fig. 2). The subgroup analysis of trials using placebo as
comparator versus trials using hypertonic saline as com-
parator showed no statistically significantly increased
intervention effect in trials using placebo (test of inter-
action P = 0.62). TSA could not be conducted due to too
few data (DIS <1 %). The sensitivity analysis with continu-
ity correction of the no-event trials was consistent with
the primary summary estimate.
Secondary outcome measures
Both trials reported that no adverse events were ob-
served; however, no detailed information on this issue
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Table 1 Characteristics of the included trials
Trial Number Setting Trial duration ICU Population Intervention Comparator Outcomes
Inclusion criteria Exclusion criteria








instability, allergy to dornase alfa,
use of nebulized acetylcysteine
and pregnancy
Nebulized dornase alfa
2.5 mg twice daily in
7 days or until resolution
of atelectasis
(1) Placebo (isotonic saline)
same volume, dosage, and
duration of treatment
Mortality
(2) Hypertonic saline (same
volume, dosage, and duration
of treatment)
Zitter et al. [19] 30 Single-centre US 12 months Mixed Mechanically ventilated
patients aged >18 years






or active nursing, concurrent
use of other investigational
drugs, and allergy to dornase
alfa, Chinese hamster ovary-
derived biologics or other
components of the active
component
Nebulized dornase alfa




Placebo (isotonic saline) same
volume, dosage, and duration
of treatment
Mortality













were available. No trials reported adequate data on other
secondary outcome measures, and the corresponding au-
thors did not supply these data upon request.
Discussion
In the present systematic review of RCTs, we found very
low level of evidence for benefit or harm of dornase alfa
use in adult critically ill patients in terms of patient- im-
portant outcome measures.
Mortality
The conventional cumulative meta-analysis of mortality
showed no statistically significant benefit or harm of dor-
nase alfa. No subgroup difference was present between pla-
cebo and hypertonic saline. Importantly, TSA highlighted
the considerable lack of data accrued, as less than 1 % of
the required information size had been accrued. Finally,
both included trials had high risk of bias, which could re-
sult in inflated point estimates. Considering the high risk
of bias and the very limited data, no firm evidence for
benefit or harm of dornase alfa use in adult critically ill pa-
tients in terms of mortality exists [21, 22].
Secondary outcome measures
The predefined patient-important secondary outcome
measures [10, 11], including duration of mechanical venti-
lation, adverse events, and length of stay, were inad-
equately reported in the included trials and were not
supplied upon request to the authors. Accordingly, the ef-
fect of dornase alfa on patient-important outcome mea-
sures in adult critically ill patients is virtually unknown.
Strengths and limitations of the review
The compliance with the recommendations of the
Cochrane Collaboration is a strength of the present sys-
tematic review, including a pre-experimentally published
protocol, a systematic literature search with no language
restrictions, independent literature search, data extraction
and risk of bias assessment by two authors, contact to
authors for further details, and the inclusion of trials irre-
spective of publication status. In addition, we evaluated
the risk of random errors with the application of TSA to
increase the robustness of the analyses. We excluded trials
Fig. 1 Risk of bias summary. Review of authors’ judgements about each
risk of bias item for each included study. Red= high risk; green= low
risk; yellow= unclear
Fig. 2 Dornase alfa and all-cause mortality. Size of squares for risk ratio reflects the weight of trial in pooled analyses. Horizontal bars represent
95 % confidence intervals
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not reporting patient important- outcome measures in
order to make the results relevant for patients and clinical
practice [10, 11]. We did not define the outcome measures
evaluated; rather, we used the definitions proposed by the
authors, which may have resulted in some degree of trial
heterogeneity. Finally, results of the predefined subgroup
analyses should be interpreted critically, as very few trials
were included in the primary analyses.
Relation to other reviews and implications for future
research
No previous systematic reviews on the use of dornase
alfa in adult critically ill patients have been published.
As highlighted in the present review, there is a lack of
firm evidence for the use of dornase alfa in this popula-
tion, as existing data are very limited (two RCTs, n = 63)
and of low quality.
In 2014, Thornby and colleagues summarized existing
evidence on dornase alfa use in pediatric patients with
non-CF pulmonary atelectasis [7]. A total of eight trials
(one RCT) and 12 case-series were included. The overall
risk of bias was high, and trials suffered from significant
heterogeneity in terms of the population of interest, the
intervention, the comparator, and the outcomes of inter-
est. Consequently, the authors concluded that there is
insufficient evidence for the efficacy of dornase alfa in
the treatment of atelectasis in pediatric patients. How-
ever, the authors suggested that dornase alfa may be use-
ful as a second-line treatment option if conventional
non-pharmacological treatment for atelectasis fails. We
believe this statement can be challenged. In everyday
clinical practice, it is essential to balance the potential
benefits and harms of an intervention. In patients with CF,
there is firm evidence that long-term treatment with dor-
nase alfa improves lung function; however, the effect on
mortality is unknown [2]. Importantly, there seems to be
an increased risk of adverse events when using dornase
alfa as compared to placebo, including rash and voice al-
terations [2]. In recent years, a number of interventions
used in the ICU have proved harmful following adequate
evaluation in high-quality trials [23–27]. Accordingly,
short-term use of dornase alfa in critically ill patients out-
side the clinical context of CF may be inappropriate with-
out firm evidence for patient-centered benefit and no
(low) risk of adverse events. Moreover, when two inter-
ventions are (presumed) equivalent, it is of clinical and fi-
nancial interest to assess costs. In 2001, Grieve and
colleagues performed a cost-effectiveness analysis of dor-
nase alfa use in children with CF [28]. The drug cost per
day was increased by a factor of 50 (£0.38 vs. £20.39) by
using dornase alfa as compared to hypertonic saline. Ac-
cordingly, it is likely that the use of dornase alfa results
in considerably increased costs as compared to stand-
ard treatment, also in critical care.
To ensure patient safety, well-powered trials with low
risk of bias assessing patient- important outcome mea-
sures are needed if dornase alfa is continued to be used in
adult critically ill patients outside the clinical context of
CF.
Conclusions
This systematic review with meta-analysis demonstrated
that the quantity and quality of evidence for the use of
dornase alfa in adult critically ill patients is very low and
that there is no firm evidence for benefit or harm as com-
pared to placebo or hypertonic saline.
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